Moffitt Study Unveils the Role of Gamma-Delta T Cells in Cancer Immunology

Study marks a significant advancement in the understanding of a specific set of immune cells and its role in patient outcomes in cancer therapy

Moffitt Cancer Center Earns North America's Project Management Office of the Year

The cancer center now advances as a finalist for the World PMO of the Year Award

Moffitt and CMIC Group Announce Partnership to Accelerate Trials

Strategic collaboration aims to enhance patient access to innovative therapies and boost international research efforts

Moffitt Cancer Center Announces Strategic Collaboration with AstraZeneca to Accelerate Oncology Cell Therapies

The collaboration will leverage Moffitt's clinical expertise to help accelerate the development of AstraZeneca's cell therapy pipeline and enhance...

Moffitt Researchers Reveal Key LAG3 Mechanisms That Could Transform Cancer Immunotherapy

New study provides detailed interaction map of LAG3, offering new pathways for developing more effective immune checkpoint inhibitors

Moffitt Researchers Develop New Chemical Method to Enhance Drug Discovery

Innovative reagent enables precise synthesis of complex sulfur-based compounds, paving the way for advanced drug development.

Moffitt Consortium Study Answers Questions About Long-Term Survivorship Following CAR T Treatment

The five-year study highlights the enduring benefits and challenges of axicabtagene ciloleucel in treating aggressive lymphomas

New Moffitt Study Explores How Antifragility Could Revolutionize Cancer Treatment

Researchers propose a framework for understanding systems that thrive on stress, potentially leading to more effective cancer therapies

Moffitt Study Uncovers Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma

Largest multimodal analysis of rare skin cancer reveals tissue-resident T cells are crucial drivers of immunotherapy response

Tumor-Infiltrating Lymphocyte Therapy Marks a Milestone in Cancer Treatment

New Moffitt commentary highlights the evolution and potential of TIL therapy

Chip Fletcher, Esq., Appointed as Moffitt Cancer Center’s General Counsel

He oversees the legal and government relations teams

Moffitt Researchers Develop Synthesis Method to Enhance Access to Cancer-Fighting Withanolides

Scalable production of the bioactive compound will advance cancer research and treatment development

Revolutionizing Ovarian Cancer Treatment With Adaptive PARP Inhibitor Therapy

Innovative Study Reveals Dose Modulation as Key to Reducing Toxicity and Combating Resistance

Moffitt Cancer Center Achieves Prestigious Nursing Magnet Recognition

This is the third time Moffitt has earned the designation

Moffitt Study Reveals New Mechanism of Drug Resistance in Melanoma Leptomeningeal Disease

Findings uncover key tumor-stroma interactions and a potential therapeutic target

News Releases